This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Fascinating observational study on hyponatraemia correction rates this week, catch-up here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) November 17, 2023
✳️10 tweet #NephJC catch-up ✳️
The challenge has been declared to the concept that rate of hyponatraemia correction is as vital as nephrologists have been telling you - to know if you agree, you need to know the studies the challenge is based upon🧵👇 pic.twitter.com/S5XVH9QqRb
